论文部分内容阅读
在一项随机、安慰剂对照实验中,OzbeyⅠ等根据尿流动力学的参数,特别是压力/流率测定,来评价多沙唑嗪在良性前列腺增生(BPH)患者中的有效姓和安全性。入选57例48-82岁的BPH患者(多沙唑嗪组29例,安慰剂组28例),然而,多沙唑嗪组有8例、安慰剂组10例因为药物副作用和不耐受尿流动力学检查[自由尿流,排尿后残余尿量(PVR)]和压力/流率测定而未纳入研究。结果显示,在1月末和6月末时,所有尿流动力学的参数有明显改善(自主最大尿流率:30．4％和28％,PVR:14ml和12ml,
In a randomized, placebo-controlled trial, Ozbey et al evaluated the validity and safety of doxazosin in patients with benign prostatic hyperplasia (BPH) based on urodynamic parameters, especially pressure / flow measurements. Fifty-seven BPH patients aged 48-82 (29 in the doxazosin group and 28 in the placebo group) were enrolled in this study. However, there were 8 in the doxazosin group and 10 in the placebo group because of drug side effects and intolerance to urine Flow cytometry [Free Urine Flow, Post-Urine Residual Urine Volume (PVR)] and pressure / flow rate measurements were not included in the study. The results showed that at the end of January and the end of June, all parameters of urodynamics improved significantly (maximal spontaneous uroflow rates: 30.4% and 28%, PVR: 14ml and 12ml,